Related references
Note: Only part of the references are listed.Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Hans Carl Hasselbalch et al.
CURRENT DRUG TARGETS (2012)
Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis
Tomer Avni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Emil Kuriakose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
Krisstina Gowin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia
Alberto Alvarez-Larran et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms
Peter Johansson et al.
LEUKEMIA & LYMPHOMA (2012)
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm
Elisa Rumi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
Richard T. Silver et al.
BLOOD (2011)
The renaissance of interferon therapy for the treatment of myeloid malignancies
Jean-Jacques Kiladjian et al.
BLOOD (2011)
Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naive Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials
Ashwani K. Singal et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders
Jerry L. Spivak et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Hans Carl Hasselbalch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
Richard T. Silver et al.
LEUKEMIA RESEARCH (2011)
A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
Hans Carl Hasselbalch
EXPERT REVIEW OF HEMATOLOGY (2011)
Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology
T. C. Pearson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Redefining the role of interferon in the treatment of malignant diseases
Sergio Bracarda et al.
EUROPEAN JOURNAL OF CANCER (2010)
Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
Min Lu et al.
EXPERIMENTAL HEMATOLOGY (2010)
Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients
F. Girodon et al.
LEUKEMIA (2010)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells
J-J Kiladjian et al.
LEUKEMIA (2010)
Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices
Ayalew Tefferi
LEUKEMIA & LYMPHOMA (2010)
Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry
Lorella Melillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
PEG-IFN-α-2a therapy in patients with myelofibrosis
Jean-Christophe Ianotto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
Thomas Stauffer Larsen et al.
HEMATOLOGY (2009)
Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
Peter J. Campbell et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis
R. T. Silver et al.
LEUKEMIA (2009)
Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer Time to change our therapeutic attitude with early upfront treatment?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Jerry L. Spivak et al.
BLOOD (2008)
The management and outcome of four pregnancies in women with idiopathic myelofibrosis
Sameer Tulpule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?
B. Cassinat et al.
LEUKEMIA (2008)
Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with Essential Thrombocythemia
Franca Radaelli et al.
HEMATOLOGICAL ONCOLOGY (2007)
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
Francesco Passamonti et al.
BLOOD (2007)
Deep cerebral vein thrombosis associated with iron deficiency anaemia in adults
Kemal Balci et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2007)
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys (R)) versus interferon alpha-2a (Roferon (R)-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia
Jeffrey H. Lipton et al.
LEUKEMIA & LYMPHOMA (2007)
The haematocrit and platelet target in polycythemia vera
Marcello Di Nisio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a
Jean-Jacques Kiladjian et al.
BLOOD (2006)
Long-term effects of the treatment of polycythemia vera with recombinant interferon-α
Richard T. Silver
CANCER (2006)
A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life
Jan Samuelsson et al.
CANCER (2006)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
AV Jones et al.
BLOOD (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia
PL Johansson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
C Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study
M Michallet et al.
LEUKEMIA (2004)
Thrombocythaemia and pregnancy
MA Elliott et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2003)
Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis
M Chawla-Sarkar et al.
APOPTOSIS (2003)
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Treating cancer with PEG intron - Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation
RM Bukowski et al.
CANCER (2002)
Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions
Y Yanai et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2001)
Treatment of the myeloproliferative disorders with 32P
NI Berlin
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells -: A gene therapy approach
A Albini et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
